[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341107-105":59,"doc-detail-341107-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","metformin-and-risk-of-hematological-cancers-in-patients-with-diabetes-a-systematic-review-and-meta-analysis","Metformin and risk of hematological cancers in patients with diabetes - a systematic review and meta-analysis","","Metformin use in patients with diabetes has shown contradictory findings regarding hematological cancers, including leukemia, lymphoma, and myeloma. This systematic review and meta-analysis searched Scopus and PubMed to evaluate the association between metformin and the odds of hematological cancers as outcomes. Eleven studies with 2,318,217 participants were included, and results indicated a decreased risk overall (OR=0.88; 95% CI 0.79-0.98). Effects were significant for multiple myeloma (OR=0.67; 95% CI 0.55-0.81), alongside evidence of heterogeneity and publication bias.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metformin-and-risk-of-hematological-cancers-in-patients-with-diabetes-a-systematic-review-and-meta-analysis/341107/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metformin-and-risk-of-hematological-cancers-in-patients-with-diabetes-a-systematic-review-and-meta-analysis/341107.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of the systematic review and meta-analysis?","Question",{"text":112,"@type":113},"To investigate whether metformin use in patients with diabetes is associated with the odds of hematological cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and time range were used to search for studies?",{"text":117,"@type":113},"Studies were searched in Scopus and PubMed using a predefined strategy for publications up to May 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the meta-analysis find about overall hematological cancer risk?",{"text":121,"@type":113},"Metformin use was associated with a decreased risk of hematological cancers (OR=0.88; 95% CI 0.79-0.98).",{"name":123,"@type":110,"acceptedAnswer":124},"Did the association differ by cancer subtype?",{"text":125,"@type":113},"In subgroup analysis, the association was significant for multiple myeloma (OR=0.67; 95% CI 0.55-0.81). Evidence also showed heterogeneity and publication bias.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},341107,1790719004,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","review  \nMetformin and risk of hematological cancersin patients with diabetes: a systematic review and meta-analysis  \nMin Wang,a Giti Noghabaei,b Tahereh Raeisi,c Dandan Li,a Hamzeh Alizadeh,d Mohammad Alizadehe  \nFrom the a Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, Henan, China; bDepartment of Internal Medicine, Iran University of Medical Sciences, Tehran, Iran; c Department of Medicine, Hormozgan University of Medical Sciences, Bandar-Abbas, Iran; dDepartment of Genetics and Breeding, University of Guilan, Rasht, Gilan, Iran; eDepartment of Medical Surgical Nursing, Mazandaran University of Medical Sciences, Sari, Iran  \nCorrespondence: Dr. Dandan Li ∙ Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, Henan, China ∙ zq231303@ [outlook.com](outlook.com) ∙ ORCID: [https://orcid](https://orcid). org/0009-0002-3358-3495  \nCitation: Wang M, Noghabaei G, Raeisi T, Li D, Alizadeh H, Alizadeh M. Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis. Ann Saudi Med 2024; 44(2): 126-134. DOI: 10.5144/0256- 4947.2024.126  \nReceived: November 20, 2023  \nAccepted: January 1, 2024  \nPublished: April 4, 2024  \nCopyright: Copyright © 2024, Annals of Saudi Medicine, Saudi Arabia. This is an open access article under the Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License (CC BY-NC-ND) . The details of which can be accessed at [http://](http://)[ ](http://)[creativecommons. org/licenses/by](creativecommons. org/licenses/by)nc-nd/4.0/  \nFunding: None.  \nThe effect of metformin use in patients with diabetes against the hematological cancers (HCs) has been contradictory. This meta-analysis, carried out on studies published in databases, aimed to investigate the association of metformin use and the odds of HCs. We systematically searched Scopus and PubMed databases to include related studies considering the relation of metformin use and the risk of HCs as outcome. Eleven studies, comprising a total of 2 318 217 participants, were included. The analysis revealed that metformin use in patients with diabetes was significantly associated with a decreased risk of HCs (OR=0.88; 95%CI: 0.79-0.98), with significant heterogeneity. In the subgroup analysis, this association was found to be significant only for multiple myeloma (OR=0.67; 95% CI: 0.55-0.81) . A significant evidence for heterogeneity and publication bias was detected. Metformin use inpatients with diabetes may be linked to the reduced risk of HCs. FUNDING: No external funding.  \nH  \nematological cancers (HCs) are a group of heterogeneous tumors, which mainly include leukemia, lymphoma and myeloma, and continue to be a significant cause of morbidity and mortality  \nworldwide.1 The mechanisms for these types of malignancies are abnormal immune or hematological cells with unlimited proliferation and blocked differentiation affecting the blood, bone marrow, and lymphatic system, which can be particularly challenging to treat.2,3 While numerous risk factors for HCs have been identified, including advanced age, genetics, ionizing radiation, viral infections, exposure to occupational or environmental toxins, obesity, smoking, sedentary lifestyle, and some autoimmune disorders,4-6 these recognized risk factors only justify a small proportion of the etiology of HCs.6 Therefore, the pursuit of innovative preventative methods continues to be a crucial endeavor to improve the prognosis of HCs.  \nStudies have consistently identified that patients with type 2 diabetes mellitus (T2DM) are at increased risk of HCs.7,8 Metformin is an oral hypoglycemic agent that has been widely used for the treatment of T2DM. Beyond its glucose-lowering effects, interestingly, metformin has been shown to potentially inhibit cancer cell growth and proliferation and improve the prognosis of patients with various kinds of cancers.9 Metformin  \n126 ANN SAUDI MED 2024 MARCH-APRIL WWW.ANNSA","cbCais4TabAjsiue","https://ap.wps.com/l/cbCais4TabAjsiue","pdf",470178,"English","# Abstract\n# Background\n# Methods\n# Results\n## Overall association\n## Subgroup analysis\n# Discussion","[{\"question\":\"What was the main aim of the systematic review and meta-analysis?\",\"answer\":\"To investigate whether metformin use in patients with diabetes is associated with the odds of hematological cancers.\"},{\"question\":\"Which databases and time range were used to search for studies?\",\"answer\":\"Studies were searched in Scopus and PubMed using a predefined strategy for publications up to May 2023.\"},{\"question\":\"What did the meta-analysis find about overall hematological cancer risk?\",\"answer\":\"Metformin use was associated with a decreased risk of hematological cancers (OR=0.88; 95% CI 0.79-0.98).\"},{\"question\":\"Did the association differ by cancer subtype?\",\"answer\":\"In subgroup analysis, the association was significant for multiple myeloma (OR=0.67; 95% CI 0.55-0.81). Evidence also showed heterogeneity and publication bias.\"}]","Metformin and risk of hematological cancers in patients with diabetes - a systematic review and meta-analysis | PDF",1790040353,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4b4825d3887d78e28d30d63f4bffd3c.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f9ad6ba6db8cbe10911338a0d3eb62a.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c3990605dde113245919ebad62f63d9.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9ea862f13a32fcba2caabe246c7ab45.webp",980,1306]